Speaker Profile
CBO, GeneDx
Biography
Lisa Gurry is the Chief Business Officer at GeneDx, where she is leading the company through its next phase of growth advancing data and information services across biopharma, health systems, and other partners to accelerate the future of precision medicine. In this role, Lisa drives GeneDxs strategic business operations and partnership models, unlocking the full potential of GeneDx Infinity, the largest rare disease dataset. She also oversees the companys communications function and collaborates on market growth strategies. With deep expertise at the intersection of healthcare, technology, and data, Lisa has a proven track record of turning bold ideas into scaled businesses. She co-founded Truveta, serving as Chief Growth Officer, Chief Marketing Officer, and Chief Operating Officer. She built the growth engine that helped secure strategic partnerships with more than 100 organizations across life sciences, healthcare, public health, and academic research. Earlier in her career, Lisa spent more than two decades at Microsoft, leading global teams and driving global growth strategies, marketing, and communications for Windows, Office, and Xbox. Lisa has a BA in communications from University of Arkansas, where she ran cross country and track. Lisa also has a daughter with several rare diseases, which culminated in a 13-year diagnostic odyssey. She is passionate about helping patients and families receive answers to transform lives.
Session Abstract – PMWC 2026 Silicon Valley
Track Chairs:
Gad Getz, Broad Institute & Alex Morgan, Khosla Ventures
PMWC Award Ceremony
• Greg Brockman, President & Co-Founder, OpenAI
• Steve Wozniak, Co-Founder, Apple
Fireside Chat
• Vinod Khosla, Khosla Ventures
• Greg Brockman, President & Co-Founder, OpenAI
Target Discovery: Beyond Genomics – Revealing Hidden Layers of Biology with AI
• Keynote: Stephen Quake, CZ Biohub
• Chair: Cindy Lawley, Olink
• Aritro Nath, City of Hope
• Massa Shoura, Phinomics
• Omar Serang, DNAnexus
Foundation Models for Human Biology: Accelerating Immunotherapy Discovery Through Multimodal AI
• Ron Alfa, Noetik
Systems Integration for Drug Discovery and AI
• Hugo Lam, Genentech
Interpretable AI Models for Multi-Modal Biomarker Discovery in Drug Development
• Vitalay Fomin, Numenos
Closing the Loop: Coupling AI with In Vivo Validation
• Gabriel Musso, biosymetrics
Interpretable AI for Biomarker Discovery: Accelerating Drug Development
• Chair: Rajat Roy, PATHOMIQ INC
• Shivanni Kummar, MD, OHSU
Can AI Really Create the Next Blockbuster Drug? Closing the Loop from Discovery to Development
• Chair: Amar Das, Guardant Health
• Ari Caroline, Weave Bio
• Dina Katabi, Emerald/MIT
• Andrei Georgescu, Vivodyne
• James Zou, Stanford
Gemini Digital Twins Accelerate Precision Medicine
• Collin Hill, Aitia
Scaling Rare Disease Discovery with AI: From Genomic Data to Therapeutic Insights
• Lisa Gurry, GeneDx
Enabling Targeted Precision Drug & Gene Delivery with Predictive AI
• Andre Watson, Ligandal
Is AI the New Drug?
• Chair: Alex Morgan, Khosla Ventures
• Michael J. Kahana, Nia Therapeutics
